Nuveen LLC Purchases New Position in Phreesia, Inc. $PHR

Key Points

• Nuveen LLC invested approximately $14.21 million in Phreesia, acquiring 555,798 shares and representing about 0.95% ownership as of the latest reporting period.
• Several brokerages have recently issued ratings on Phreesia, with a consensus rating of "Buy" and a target price of $32.27, indicating positive analyst sentiment.
• Phreesia's revenue for the last quarter was $115.94 million, showing a 14.5% increase year-over-year, despite reporting a negative net margin of 9.83% and a loss of ($0.07) EPS for the quarter.

Nuveen LLC acquired a new stake in Phreesia, Inc. (NYSE:PHR - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 555,798 shares of the company's stock, valued at approximately $14,206,000. Nuveen LLC owned 0.95% of Phreesia as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of PHR. Johnson Financial Group Inc. increased its holdings in Phreesia by 381.3% in the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock valued at $28,000 after purchasing an additional 896 shares during the period. Quarry LP increased its holdings in Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock valued at $71,000 after purchasing an additional 1,923 shares during the period. KBC Group NV acquired a new stake in Phreesia in the first quarter valued at $74,000. CWM LLC increased its holdings in Phreesia by 994.9% in the first quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after purchasing an additional 3,671 shares during the period. Finally, NewEdge Advisors LLC increased its holdings in Phreesia by 12.1% in the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock valued at $107,000 after purchasing an additional 459 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on PHR shares. DA Davidson upgraded Phreesia to a "strong-buy" rating in a report on Tuesday, July 22nd. Citigroup restated a "buy" rating on shares of Phreesia in a report on Wednesday, May 28th. KeyCorp increased their price objective on Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Wall Street Zen upgraded Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Finally, Truist Financial increased their price target on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. One investment analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $32.27.

Phreesia Stock Up 2.1%

Shares of Phreesia stock traded up $0.61 during trading on Monday, reaching $30.36. 1,047,812 shares of the company traded hands, compared to its average volume of 523,506. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $31.04. The company has a 50 day moving average price of $27.49 and a 200-day moving average price of $26.39. The firm has a market capitalization of $1.81 billion, a PE ratio of -41.03 and a beta of 0.71.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings data on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $115.94 million for the quarter, compared to analysts' expectations of $115.00 million. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The business's revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.05) EPS. Phreesia has set its FY 2026 guidance at EPS. As a group, equities research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Activity at Phreesia

In other news, Director Mark Douglas Smith sold 7,000 shares of the stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $29.00, for a total transaction of $203,000.00. Following the transaction, the director owned 37,353 shares of the company's stock, valued at $1,083,237. This represents a 15.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Evan Roberts sold 1,892 shares of the stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $26.89, for a total transaction of $50,875.88. Following the transaction, the chief operating officer directly owned 772,915 shares in the company, valued at $20,783,684.35. This trade represents a 0.24% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,882 shares of company stock worth $1,513,007. 5.50% of the stock is currently owned by insiders.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.